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This is anOpeAbstract – The development and application of new European software for cancer risk assessment after
radiation exposure from a nuclear accident is described here. This software computes lifetime risks for
several types of cancer and is intended to provide information for consideration by decision makers in the
urgent and transition phases of nuclear emergencies. Such information on radiation related cancer risks can
be useful to consider in the identification of protective measures (e.g., sheltering, evacuation, allocation of
individuals to screening programmes and advice to take thyroid protection medication) in a differential way
(i.e., for particularly susceptible sub-groups of a population). A description and application of the software
for converting dose limits applicable after nuclear accidents into corresponding cancer risks, based on
German population data, has already been published. Therefore, only a brief description of the main features
of the software and some new illustrative results based on Swiss population data are given here, with some
additional information on the input and output specification of the software.
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previously available for use immediately after a nuclear
accident. For example, after the Fukushima nuclear accident
(Janssens, 2013) on 11thMarch 2011, two years elapsed
between accident occurrence and the publication of the World
Health Organization (WHO) health risk assessment (WHO,
2013) report. This two-year period, after the event, was
required for assessing doses, developing a risk assessment
framework and developing the risk assessment software, but
did not allow enough time to include a full explicit
mathematical treatment of risk uncertainties. Lessons learned
after Fukushima (Walsh, 2016) have emphasized the need to
close such potential future time gaps between accidents and
health risk assessments. Therefore, funding was provided by
the European Union-CONFIDENCE (COping with uNcer-
tainties For Improved modelling and DEcision making in
Nuclear emergenCiEs) project to develop health risk assess-
ment (HRA) software (the EU-CONFIDENCE software tool)
designed to be immediately available after a nuclear accident.
The tool is based on the HRA methodological framework for
assessing cancer risks after the Fukushima accident as
developed and recommended by a WHO expert groupding author: linda.walsh@uzh.ch
nAccess article distributed under the terms of the Creative CommonsA
unrestricted use, distribution, and reproduction in any m(WHO, 2013; Walsh et al., 2014) and by the German ProZES
project group (Jacob et al., 2017; Ulanowski et al., 2016).
This WHO Fukushima methodology has been applied
here to calculate the risks of all solid cancers and leukaemia
per unit relevant organ dose from contemporary models of
radiation risk and for an illustrative modern European
population i.e., the example calculations have been performed
using the demographic data and disease statistics for
Switzerland.
An important feature of the tool is a full mathematical
treatment of uncertainties in the calculated risks, so that the
risks can include confidence intervals. Although Swiss
population data are considered here, the software tool also
incorporates data for four Nordic countries and Germany and
can be extended for other countries.
2 Methods
The methods are fully presented by (Walsh et al., 2019)
and therefore only a brief description is given here. Models
for additive and multiplicative excess risks in the same
cancer site groupings applied by the WHO (2013) were
applied to calculate lifetime risks attributable to organ/tissue
doses from radiation exposures after a nuclear accident
(Tab. 1). The conventional lifetime attributable risk (LAR)
(Thomas et al., 1992; Vaeth and Pierce, 1990) was applied.ttributionLicense (https://creativecommons.org/licenses/by/4.0), which permits
edium, provided the original work is properly cited.
Table 1. Cancer incidence outcomes included in the new CONFIDENCE software.
Cancer groupings applied and source of additive and multiplicative excess risk to dose response models Organ dose type required
All solid cancers (ICD10:C00-C80)
Japanese A-bomb Life Span Study (LSS)
Cohort:1958–2009 (Grant et al., 2017)
Colon
All leukemia (ICD10:C91-C95), excluding CLL (ICD10:C91.1, C91.4) and ATL (ICD10:C91.5)
LSS cohort:1958–2001 (Hsu et al., 2013)
Red bone marrow
Thyroid cancer (ICD10:C73)
LSS cohort:1958–1999 (Jacob et al., 2014)
Thyroid
Female breast cancer (ICD10:C50)
Pooled study of eight cohorts (Preston et al., 2002)
Breast
Fig. 1. Schematic diagram giving the definitions of Lifetime Baseline Risk (LBR) and Lifetime Attributable Risk (LAR) of cancer.
Requirements for calculating these two quantities, for the all solid cancer grouping and Swiss females, are shown in a simplified schematic
representation at the top of the diagram. The requirements, from left to right, are: age specific cancer incidence rates for 2010–2014 in
Switzerland (bfs.ch); Swiss survival curves for 2016 (calculated with data from www.who.org); and radiation dose response curves for the
excess relative risk as a function of colon dose (Gy) from the most recent analysis of cancer incidence in the life span study (LSS) of Hiroshima
and Nagasaki A-bomb survivors (with risk parameters taken from Table 5 of Grant et al., 2017).
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examples of the input data required for calculating LAR are
given in Figure 1.
Calculations of LAR are associated with large uncertainties
that were quantified in this tool by applying stochastic
simulations with a methodology previously described
(Ulanowski et al., 2016; Jacob et al., 2014).
The following uncertainties were included:
– the radiation risk model parameters from the excess risk
models (given in Tab. 1) were sampled from a multivariate
normal distribution using best estimates of all the model fit
parameters, including those for the model baseline, and
parameter covariance matrices;– a factor for apportioning additive and multiplicative
radiation risk contributions was sampled from a uniform
distribution;– dose rate effects were sampled from a lognormal
distribution with a geometric mean of 1.0;– the minimum latency periods were sampled from a sigmoid
distribution;– uncertainties in age specific cancer incidence rates were
sampled from Poisson distributions;– the doses were sampled from a normal distribution (here,
but the tool allows a choice of other distribution forms),
with means of 100mGy organ doses appropriate to the
cancer outcome type considered, Tab. 1).
Fig. 2. Male and female all solid cancer baseline (dark grey) and
radiation (light grey with error bars) risks in cases per 10,000 persons
calculated from LBR and the LAR for 100mGy mean colon dose
(normally distributed, s = 50mGy). Based on Swiss population data
and error bars for 95% confidence intervals.
Fig. 3. Male and female leukaemia baseline (dark grey) and radiation
(light grey with error bars) risks in cases per 10,000 persons calculated
from LBR and the LAR for 100mGy mean red bone marrow dose
(normally distributed, s = 50mGy). Based on Swiss population data
and error bars for 95% confidence intervals.
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Input:-
Outcome =ASC (all solid cancer)
Country = Switzerland
Gender =Male
Age-at-exposure = 1 (years)
Dose distribution: normal, m= 0.1Gy, s = 0.05Gy
Output:-
Time (year) Time-integrated risk (%)
BRtime or LBR (baseline) ARtime or LAR (radiation-attributable)
Mean Median (95% CI) Mean Median (95% CI)
10 0.04 0.03 (0.00–0.13) 0.00 0.00 (0.00–0.01)
20 0.16 0.14 (0.05–0.37) 0.26 0.05 (0.00–1.77)
50 2.59 2.56 (1.88–3.52) 1.06 0.48 (0.01–5.21)
Lifetime 39.90 39.83 (35.64–44.70) 3.80 2.99 (0.08–12.18)
LBR: Lifetime Baseline Risk (also given as baseline risk at different times since exposure, BRtime); LAR: Lifetime Attributable Risk (also given
as attributable risk at different times since exposure, ARtime).Radiation-related cancer risks, in terms of LAR, were
estimated for both males and females initially exposed as
infants (age 1 year), children (age 10 years) or adults (age
20 years) applying demographic and health statistics data from
a contemporary illustrative European population (Swiss
population, WHO and www.krebs.bfs.admin.ch). Table 2
gives an example of the input and output specification of the
software.
3 Results
The LAR and lifetime baseline risk (LBR) have been
simply converted from probabilities (Tab. 2) to numbers of
excess cases and number of baseline cases per 10,000 persons,
for age at exposure 1, 10 and 20 years, and are given inFigures 2 and 3, for all solid cancers and leukaemia,
respectively.
The results for all solid cancers (Fig. 2) show that females
have a larger radiation risk than males over a lifetime, but
males have a larger lifetime baseline risk than females. The
grouping “all solid cancer” will provide risk estimates with a
higher statistical power than is obtainable for individual cancer
sites, due to the much larger number of all solid cancers
compared to the numbers of site specific cancers, in the data-
sets used to fit the radiation dose response curves for the
additive and multiplicative excess risk to dose response models
(obtained in the studies cited in Tab. 1), see Figure 1. However,
it is noteworthy that the 95% confidence intervals on the
numbers of all solid cancer cases expected per 10,000 persons,
at 100mGy colon dose, over lifetime are still large e.g., 462
(95%CI: 12; 1258), 375 (95%CI: 8; 879) and 294 (95%CI: 6;
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respectively.
Figure 3 gives the results for leukaemia. Here, the radiation
risk sex differences, reflect those differences reported in the
additive and multiplicative A-bomb life span study risk models
(Hsu et al., 2013) i.e., the multiplicative model did not support
a gender effect but the additive model did, with a female to
male ratio of 0.66. Due to the equal average probabilities of
additive and multiplicative transfer types in the LAR
calculations applied here, it can be seen that the male radiation
lifetime risks are consistently slightly larger than the female
risks at the same doses and for all ages at exposure considered.
The male leukaemia baseline risks over a lifetime are also
consistently larger than the female risks for all three ages at
exposure considered.
4 Discussion and conclusions
Given the time lapse between the Fukushima accident and
the development of HRA software mentioned in the
introduction, there is great potential for risk assessment
tools that have been fully developed and are ready for
operation, before any nuclear accident actually takes place.
However, in adopting a “WHO” framework and developing
software for use in health risk assessment, it is important to
avoid misunderstandings when interpreting lifetime attribu-
table risks, LAR, as presented here. Although LAR values can
be based on individual (but not person specific) doses, they
cannot represent an individual’s cancer risks because there is
generally no information on important co-factors that
influence a particular individual’s cancer risk (e.g., individual
radiation sensitivity; genetic pre-disposition to cancer and
lifestyle factors). Furthermore, the Swiss population-based
incidence and survival curves, used in the LAR calculations,
only represent average values for the national population
considered at one point in time. LAR should therefore be
interpreted as an average risk for specific ages at exposure and
genders. The number of baseline and radiation related cases
observed in the future will include other sources of variability
(uncertainty), dependent on several factors including the size of
the population group, and future developments in the secular
trends in population statistics (on which the risks are based),
which are not accounted for in the software HRA tool. Further
work has also been done onmethods that reduce thedependence,
of radiation related risk assessments on population statistics and
survival curves (Ulanowski et al., 2019). Initial work has also
been undertaken to assess the usefulness of directly integrated
the risk assessment tool into currently available decision support
systems (e.g., JRODOS, Ehrhardt and Weis, 2000) and this is a
topic for future developments.
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